We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 42.00
Ask: 45.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.143%)
Open: 43.50
High: 43.50
Low: 42.40
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio News - Molendotech Secures First Funding

19 Feb 2018 07:00

RNS Number : 2030F
Frontier IP Group plc
19 February 2018
 

 

FIPP RNS Reach

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

Portfolio News - Molendotech Secures First Funding

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce the completion of a first fundraising for portfolio company Molendotech Limited ("Molendotech" or "the Company"). Molendotech has received a commitment totalling £0.5 million which will be invested in three tranches. Frontier IP will hold approximately 14% of the issued share capital of Molendotech following the investment of the third tranche.

 

Molendotech develops a novel test which is able to identify the concentration of faecal bacteria in water. Molendotech's rapid, point-of-use test to determine water quality enables more informed decision-making about the use of water and significantly improves the ability to identify and track any pollution source. The Company recently entered into a collaboration agreement with Palintest Limited ("Palintest"), a subsidiary of FTSE-100 company Halma plc, for the development and licencing of water testing products.

 

This capital has been raised to support the development of further water testing products, initial sales and its expansion into new markets.

 

Professor Simon Jackson, Director of Molendotech, said, "Securing significant investment at this early stage is a great achievement and confirmation of the commercial potential of Molendotech products. This funding will enable us to realise our business plans and develop a portfolio of water testing assays for different markets."

 

Neil Crabb, Chief Executive of Frontier IP, said, "We are delighted that Molendotech has attracted significant backing so soon after its formation. This funding is a clear demonstration of confidence in both the technology and the stature of the partners it is able to bring in."

 

For further information:

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

T: 0131 240 1251

Cenkos Securities plc (Nominated Adviser and Joint Broker)

Neil McDonald / Beth McKiernan

T: 0131 220 6939

Peterhouse Corporate Finance Limited (Joint Broker)

Lucy Williams

T: 020 7469 0935

Kreab (Financial PR)

Robert Speed / Matthew Jervois

T: 020 7074 1800

 

Notes to Editor:

 

About Frontier IP Group plc

 

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.

 

About Molendotech

 

Molendotech Limited was created to develop and commercialise the work of Simon Jackson, Professor of Environment and Human Health within the Plymouth University, Peninsula Schools of Medicine and Dentistry. Molendotech develops a rapid assay to screen water for faecal contamination. Current tests on the market may take hours or even days to show results, whereas Molendotech's technology typically produces results in under 15 minutes. A patent has been filed in relation to the technology, which has already been granted in the US for recreational waters.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZMGMZVRZGRZM
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.